Antineoplastics

Antineoplastics Reactions 1680, p44 - 2 Dec 2017 Posterior reversible encephalopathy syndrome: case report A 14-year-old man developed posterior reversible encephalopathy syndrome (PRES) during treatment with asparaginase [L-asparaginase], prednisolone, vincristine and daunorubicin [routes, time to reaction onset not stated and not all dosage stated]. The man, who had acute lymphoblastic leukemia, started receiving St. Jude Chemotherapy Protocol consisting of asparaginase, prednisolone, vincristine and daunorubicin. He started alkaline hydration and allopurinol and therapies for tumor lysis syndrome. His creatinine level decreased to th 0.7 mg/dL with hydration. Till 14 day of chemotherapy, he had 2 th received asparaginase 10,000 units/m /day for 4 days. On 14 day of remission induction therapy, he developed sudden onset clouding of consciousness, inability to speak and a tonic clonic seizure lasting for 2-3 minutes in the upper and lower extremities. Laboratory results revealed white cell count of 1500 µ/mL, Hb level of 12.3 gr/dL, platelets count of 92,000 µ/mL, uric acid level of 3.9 mg/dL, creatinine level of 0.69 mg/dL, urea level of 16 mg/dL, sodium level of 125 mEq/L, magnesium level of 4.9 mEq/L, potassium level of 3.45 mg/dL and calcium level of 9.4 mg/dL. His seizures were controlled with midazolam therapy, and he started receiving phenytoin and dexamethasone. His sodium level was found to be at 125 mEq/L, despite 7 mEq/kg sodium chloride support in total fluid. Later, he received sodium raising deficit therapy. His cranial MRI imaging revealed, partially symmetrical and hyperintense lesions at T2 and FLAIR in both cerebellar white matters, the bilateral frontal superior and midfrontal gyrus and the parietal lobe in the posterior interhemispheric fissure in the occipitoparietal regions in the bilateral temporo-occiptal junctions. Partial diffusion restriction was found in lesions in the bilateral occipitoparietal regions and the cerebellum, while free diffusion was found in the others, and these findings were consistent with PRES. The man’s general condition improved on day 2 of treatment, and his consciousness returned. After 15 days, control cranial MRI revealed significant improvement in the lesions. The sodium support requirement persisted on day 21. Tubulopathy was considered, and he started receiving fludrocortisone. No neurological deficit was observed and clinical condition improved. His IV sodium support was gradually discontinued and he was continued on chemotherapy. He eventually completed his remission induction treatment. Author comment: "Posterior reversible encephalopathy syndrome (PRES), may be due to different causes. It may develop secondary to hypertension, renal decompensation, electrolyte imbalance, and chemotherapeutic drugs." "We therefore think that hyponatremia and chemotherapeutic agents account for the clinical picture in our case." Eroglu N, et al. A Case of ALL Developing Posterior Reversible Encephalopathy Secondary to Hyponatremia. Journal of Pediatric Hematology/Oncology 39: e476-e478, No. 8, Nov 2017. Available from: URL: http://doi.org/10.1097/ MPH.0000000000000827 - Turkey 803285165 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Antineoplastics

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/antineoplastics-rYtr0B8ekQ
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-38975-2
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial